Inhibition of neddylation potentiated natural (Figs. 1 and 2, and Supplementary Figs. 2 and 4) and antibody-mediated degranulation of NK cells against MM cells (Figs. 3 and 4, and Supplementary Figs. 6–8), where Daratumumab and Elotuzumab are fully human and humanized monoclonal antibodies targeting CD38 and SLAMF7/CS1 respectively, approved for the treatment of MM [46, 60]. The gene discussed is SLAMF7; the disease is Miyoshi myopathy.